ZNF133 is a potent suppressor in breast carcinogenesis through dampening L1CAM, a driver for tumor progression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer heterogeneity necessitates precise molecular indicators for effective treatment.
• Current classification relies on estrogen/progesterone receptors and human epidermal growth factor 2, but novel markers are needed.

Purpose of the Study:

• To investigate the role of ZNF133 in breast cancer development and progression.
• To elucidate the molecular mechanism by which ZNF133 affects breast cancer cells.
• To identify ZNF133 and L1CAM as potential diagnostic and prognostic markers.

Main Methods:

• Assessed ZNF133 expression in relation to patient survival and tumor stage.
• Identified ZNF133 as a transcription repressor associated with the KAP1 complex.
• Investigated the effect of the ZNF133/KAP1 complex on target genes, including L1CAM.
• Evaluated the impact of ZNF133 on breast cancer cell proliferation, invasion, growth, and metastasis in vitro and in vivo.

Main Results:

• ZNF133 expression is negatively correlated with poor survival and advanced pathological staging in breast cancer.
• ZNF133 transcriptionally represses genes involved in cell proliferation and motility, such as L1CAM.
• The ZNF133/KAP1 complex inhibits breast cancer cell proliferation and invasion in vitro.
• ZNF133 suppresses breast cancer growth and metastasis in vivo by reducing L1CAM transcription.

Conclusions:

• ZNF133 functions as a tumor suppressor in breast cancer.
• ZNF133 and L1CAM levels are valuable for breast cancer diagnosis and prognosis.
• The ZNF133/KAP1 complex presents a novel therapeutic strategy and intervention target for breast cancer.